Pay in 4 interest-free payments of $6.92 Learn more
Ships within 48 hours · Estimated delivery Sep 24 - Sep 29
Semaglutide is currently being investigated in two large phase III clinical trial programs for treating obesity: the STEP program, which aims to obtain regulatory approval for semaglutide as an anti-obesity drug and is evaluating cardiovascular outcomes in 17,500 patients
While the results are promising, its important to have realistic expectations
Presented for research literature review only Liu TF et al
Whilst most dermatological side effects are mild and self-limiting, recognising when a rash may signify a more serious reaction is crucial for patient safety
US$ 24.38
US$ 25.44
US$ 25.50
US$ 27.78
US$ 26.66
US$ 23.05
